Q3 2020: Strong Third Quarter

Merck KGaA, Darmstadt, Germany grew significantly in the third quarter. In comparison with the year-earlier quarter, Group net sales increased by 9.7% to € 4.4 billion.

OVERVIEW AND OUTLOOK

Overview of Q3 2020
  
  • Group net sales increase organically by 7.2%; EBITDA pre up 19.8% organically, excluding release of the provision for patent dispute with Biogen Inc.
  • Life Science grows organically by 15.6%, mainly thanks to the Process Solutions business
  • Mavenclad and Bavencio drive organic growth of Healthcare; recovery in the Fertility franchise
  • Semiconductor Solutions business of Performance Materials grows organically by 8.0%

Outlook for fiscal 2020

  • Company expects organic sales growth of 4% to 5% over the previous year and Group net sales of between € 17.1 billion and € 17.5 billion
  • Organic growth of EBITDA pre over the previous year excluding provision release between 6% and 8% expected, EBITDA pre in a range between € 5.05 billion and € 5.25 billion
852 852 Pull Quote Oschmann Stefan 2018 Small 852 852 Pull Quote Oschmann Stefan 2018 Small

The superb results of the third quarter once again underscore the strength of our diversified business model.

Stefan Oschmann

Chairman of the Executive Board and CEO of Merck KGaA, Darmstadt, Germany

Conference calls for the media and analysts

Annual Reports Archive

Find previous Annual Reports, Corporate Governance Reports & Statements in our archive.
Read more

Related News

View All News
  1. Press Releases

    Merck KGaA, Darmstadt, Germany, Reports Strong Third Quarter

    Merck KGaA, Darmstadt, Germany, grew significantly in the third quarter. In comparison with the year-earlier quarter, Group net sales increased by 9.7% to € 4.4 billion.

    2020/11/12

Andreas Cezanne

Financial Communications

Constantin Fest

Head of Investor Relations

+49 6151 72-5271

+49 6151 72 91-5271

Upcoming Event

View All Events

Our interactive Share Price Tool provides you with all the information you need. You can retrace our development within the last ten years or follow it in real time – or compare our share price to various indices.

Check Share Price